Elizabeth Berry-Kravis is professor of child neurology at Rush University Medical Center in Chicago.
Elizabeth Berry-Kravis
Professor
Rush University Medical Center
From this contributor
Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Analysis offers new hope for failed fragile X drug
By
Jessica Wright
26 February 2019 | 6 min read
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
A mouse model of fragile X syndrome lacks a key feature of the condition, prompting researchers to look for other ways to test treatments.
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
By
Jessica Wright
24 May 2016 | 6 min read
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
By
Nicholette Zeliadt
17 February 2015 | 5 min read
Explore more from The Transmitter
Cracking the code of the extracellular matrix
Despite evidence for a role in plasticity and other crucial functions, many neuroscientists still view these proteins as “brain goop.” The field needs technical advances and a shift in scientific thinking to move beyond this outdated perspective.
Cracking the code of the extracellular matrix
Despite evidence for a role in plasticity and other crucial functions, many neuroscientists still view these proteins as “brain goop.” The field needs technical advances and a shift in scientific thinking to move beyond this outdated perspective.
By
Anna Victoria Molofsky
17 January 2025 | 5 min read
Huntington’s disease gene variants past a certain size poison select cells
The findings—providing “the next step in the whole pathway”—help explain the disease’s late onset and offer hope that it has an extended therapeutic window.
Huntington’s disease gene variants past a certain size poison select cells
The findings—providing “the next step in the whole pathway”—help explain the disease’s late onset and offer hope that it has an extended therapeutic window.
By
Angie Voyles Askham
16 January 2025 | 6 min read
X marks the spot in search for autism variants
Genetic variants on the X chromosome, including those in the gene DDX53, contribute to autism’s gender imbalance, two new studies suggest.
X marks the spot in search for autism variants
Genetic variants on the X chromosome, including those in the gene DDX53, contribute to autism’s gender imbalance, two new studies suggest.
By
Holly Barker
16 January 2025 | 6 min read